Drugs / CC-95775
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04089527 | Oct 2019 → Oct 2021 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-95775 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04089527 ↗ |
| Route | Oral | “treated with oral capsules of CC-95775” NCT04089527 ↗ |